出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年2月
Wearable Injectors Market – Global Forecast to 2029
ウェアラブルインジェクター市場 : タイプ (オンボディ、オフボディ)、テクノロジー (スプリング、モータードライブ、拡張バッテリー、ロータリーポンプ)、適応症 (糖尿病、免疫腫瘍学、心臓血管、慢性疼痛)、エンドユーザー (病院＆クリニック、在宅ケア) – 2029年までの世界予測
Wearable Injectors Market by Type(On-body, Off-body), Technology (Spring, Motor Drive, Expanding Battery, Rotary Pump), Indications (Diabetes, Immuno- Oncology, Cardiovascular, Chronic Pain), End Users (Hospital & Clinic, Homecare) – Global Forecast to 2029
| ページ数 | 237 |
| 図表数 | 259 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global wearable injectors market is projected to reach USD 15.1 billion by 2029 from USD 8.4 billion in 2023, at a CAGR of 10.3% during the forecast period.
世界のウェアラブルインジェクター市場は、予測期間中のCAGR 10.3%で、2023年の84億米ドルから2029年までに151億米ドルに達すると予測されています。
Precise, user-friendly design, efficient delivery of large molecules, favorable reimbursements, numerous applications in drug delivery, the seamless subcutaneous flow of drugs, rise in the adoption of chronic diseases, and increased adoption of convenient drug delivery devices. The increased cost of wearable injectors and the high use of injection pens are challenges to growth in wearable injectors.
“On body wearable injectors segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.”
On-body injectors, often equipped with the wisdom of smart features, offer a window into medication administration and adherence. Missed doses become a distant memory, usage patterns focus, and timely reminders keep the treatment waltz in rhythm, leading to improved health and fewer complications. Miniaturization promises a lighter, more discreet, while advancements in data security and accessibility will break down the barriers to entry. As manufacturers focus on affordability and diverse needs, on-body injectors have the potential to democratize healthcare, empowering millions to take control of their health with newfound confidence and independence.
“The rotary pump segment accounted for the highest growth during the forecast period.”
Unlike spring-based or motor-driven systems, rotary pumps deliver unwavering accuracy in medication dosage. Their fluid mechanics ensure consistent flow, minimizing the risk of errors and maximizing therapeutic effectiveness, particularly for medications requiring precise micro-doses. will drive the growth of the wearable injectors market. Rotary pumps achieve this magic with their smooth, low-pressure delivery, reducing pain and discomfort for patients, especially those with needle anxieties. Plus, their compact design translates to discreet and convenient use, seamlessly integrating into daily routines.
“Immuno oncology segment accounted for the second largest share of the market.”
Wearable injectors, with their user-friendly designs and intuitive interfaces, become an extension of the patient’s therapeutic rhythm, reducing the dissonance of missed doses and ensuring sustained efficacy. This harmonization potentially amplifies treatment outcomes, particularly in immuno-oncology where precise administration is crucial. However, the score of healing can be laced with discomfort, a disruptive counterpoint for patients already battling their disease. Here, wearable injectors offer a gentle counter-melody. Their low-pressure delivery minimizes the cacophonous notes of injection anxiety, allowing patients to focus on the therapeutic crescendo within. This newfound autonomy, the ability to self-administer at their own tempo, liberates patients from the clinical constraints, transforming them into soloists in their own health journey.
“Hospitals and clinics are the end-user segment held the largest market share in the wearable injectors market.”
Wearable injectors are quietly claiming center stage, emerging as discreet allies in chronic disease management. These compact companions, adhering directly to the body, orchestrate medication delivery with precision, often minimizing the overall number of injections and granting patients an unprecedented level of control over their treatment. The allure of these miniature maestros lies in their ability to transcend the confines of hospital walls. Imagine ditching the sterile atmosphere and lengthy waits for home-based medication administration. Wearable injectors liberate patients from the shackles of institutional routines, reducing unnecessary clinic visits and the associated risk of hospital-acquired infections. This shift not only empowers individuals but also aligns with the digital health revolution, paving the way for seamless connectivity and remote monitoring of chronic conditions.
“North America to Witness Significant Growth From 2023 to 2029.”
Wearable injectors market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa and GCC. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the wearable injectors market, commanding the largest market share throughout the forecast period. North America boasts a well-developed healthcare infrastructure, fertile ground for nurturing research and development of cutting-edge technologies. Leading manufacturers find a welcoming stage here, their expertise fueling a thriving ecosystem of collaboration with universities, research labs, and other industry players. This collaborative spirit results in a constant crescendo of innovation, propelling the wearable injector market forward.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 50%, and Tier 3 – 15% • By Designation: C-level – 35%, Director-level – 40%, and Others – 25% • By Region: North America – 30%, Europe – 25%, APAC – 20%, Latin America – 15%, Middle East & Africa – 7% GCC- 3%
Some of the prominent players in the wearable injectors market are Amgen Inc. (US), Medtronic PLC (Europe), Insulet Corporation (US), Tandem Diabetes Care, Inc. (US), United Therapeutics Corporation (US), Abbvie Inc. (US), Gerresheimer AG (Germany), Becton Dickinson and Company (US), West Pharmaceutical Services Inc. (US), Ypsomed AG (Switzerland), Enable Injections (US), Subcuject APS (Denmark), Cequr Simplicity (Switzerland), Mannkind Corporation (US), Sonceboz (Switzerland), CC Bio (Japan), Elcam Drug Delivery Devices (Israel), Stevanato Group (Italy), Debiotech SA (Switzerland), Bexson Biomedical (US), Nemera (France), LTS Lohmann Therapie Systeme AG (Germany), Kymanox Corporation (US), Novo Engineering (US), and Eoflow (South Korea).
Research Coverage
This report studies the wearable injectors market based on type, technology, indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
• Analysis of key drivers (increasing prevalence of diabetes, technological advancements in wearable injectors devices, advent of artificial intelligence in wearable injectors, favorable reimbursements scenario in major markets, low -complexity, easy- to- use wearable injection platform), restraints (high cost of wearable injectors, oral insulin as an alternative drug delivery method), opportunities (increasing research and development activities and strategic partnerships and increased adoption of on-body wearable injectors), and challenges (needlestick injuries and misuse of injection pens) influencing the growth of wearable injectors market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in wearable injectors market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in wearable injectors market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.
Table of Contents
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 33
1.3 INCLUSIONS & EXCLUSIONS 34
1.4 MARKET SCOPE 34
1.4.1 MARKETS COVERED 34
1.4.2 REGIONS COVERED 35
1.4.3 YEARS CONSIDERED 35
1.4.4 CURRENCY CONSIDERED 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 36
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 36
1.6.1 RECESSION IMPACT: WEARABLE INJECTORS MARKET 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
FIGURE 1 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 38
2.1.1.1 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
FIGURE 2 PRIMARY SOURCES 40
2.1.2.1 Key data from primary sources 41
2.1.2.2 Key industry insights 42
2.1.2.3 Breakdown of primary interviews 42
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 43
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 43
2.2 MARKET SIZE ESTIMATION 43
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC. 44
FIGURE 8 SUPPLY-SIDE ANALYSIS OF TOP COMPANIES: WEARABLE INJECTORS MARKET (2022) 45
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, 2023–2029 46
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47
FIGURE 11 TOP-DOWN APPROACH 47
2.3 DATA TRIANGULATION 48
FIGURE 12 MARKET DATA TRIANGULATION 48
2.4 MARKET SHARE ESTIMATION 49
2.5 STUDY ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 49
2.6.1 METHODOLOGY-RELATED LIMITATIONS 49
2.6.2 SCOPE-RELATED LIMITATIONS 49
2.7 RISK ASSESSMENT 50
TABLE 2 RISK ASSESSMENT: WEARABLE INJECTORS MARKET 50
2.8 IMPACT OF ECONOMIC RECESSION ON WEARABLE INJECTORS MARKET 50
3 EXECUTIVE SUMMARY 51
FIGURE 13 WEARABLE INJECTORS MARKET, BY TYPE, 2023 VS. 2029 (USD MILLION) 51
FIGURE 14 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023 VS. 2029 (USD MILLION) 52
FIGURE 15 WEARABLE INJECTORS MARKET, BY INDICATION, 2023 VS. 2029 (USD MILLION) 53
FIGURE 16 WEARABLE INJECTORS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION) 54
FIGURE 17 REGIONAL SNAPSHOT OF WEARABLE INJECTORS MARKET 55
4 PREMIUM INSIGHTS 56
4.1 WEARABLE INJECTORS MARKET OVERVIEW 56
FIGURE 18 INCREASING PREVALENCE OF CHRONIC DISEASES AND RISING HEALTHCARE EXPENDITURE TO DRIVE MARKET 56
4.2 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER & REGION, 2022 57
FIGURE 19 CHINA AND HOSPITALS AND CLINICS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 57
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES: WEARABLE INJECTORS MARKET 58
FIGURE 20 US TO REGISTER HIGHEST MARKET GROWTH RATE DURING FORECAST PERIOD 58
4.4 WEARABLE INJECTORS MARKET: DEVELOPED VS. EMERGING ECONOMIES 59
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES: WEARABLE INJECTORS MARKET 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing prevalence of diabetes among geriatric population 61
TABLE 3 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045 61
5.2.1.2 Technological advancements in wearable injectors 61
5.2.1.3 Use of artificial intelligence in diabetes care devices 62
5.2.1.4 Favorable reimbursement scenario 63
5.2.1.5 Development of low-complexity and easy-to-use wearable injectors 63
5.2.2 RESTRAINTS 64
5.2.2.1 High cost of wearable injectors and lack of reimbursement plans in emerging economies 64
5.2.2.2 Increased focus on alternative drug delivery methods 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 Increased number of R&D activities and strategic partnerships 65
5.2.3.2 Growing adoption of on-body wearable injectors 65
5.2.4 CHALLENGES 66
5.2.4.1 Lack of training and education for using new delivery devices 66
5.3 INDUSTRY TRENDS 66
5.3.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY SYSTEMS 66
5.3.2 RISING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS 67
TABLE 4 RECENT COLLABORATIONS IN WEARABLE INJECTORS MARKET 67
5.3.3 INTEGRATION OF LIQUID SILICONE RUBBER TECHNOLOGY IN WEARABLE HEALTH MONITORING AND DRUG DELIVERY DEVICES 67
5.4 TECHNOLOGY ANALYSIS 68
5.5 SUPPLY CHAIN ANALYSIS 69
FIGURE 23 SUPPLY CHAIN ANALYSIS: WEARABLE INJECTORS MARKET 69
5.6 VALUE CHAIN ANALYSIS 70
FIGURE 24 VALUE CHAIN ANALYSIS: WEARABLE INJECTORS MARKET 71
5.7 ECOSYSTEM MARKET/MAP 71
FIGURE 25 ECOSYSTEM MARKET/MAP: WEARABLE INJECTORS MARKET 71
5.8 TRADE ANALYSIS 72
TABLE 5 IMPORT AND EXPORT DATA FOR WEARABLE INJECTORS, BY COUNTRY 72
5.9 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 6 PORTER’S FIVE FORCES ANALYSIS: WEARABLE INJECTORS MARKET 72
5.9.1 INTENSITY OF COMPETITIVE RIVALRY 73
5.9.2 BARGAINING POWER OF SUPPLIERS 73
5.9.3 BARGAINING POWER OF BUYERS 73
5.9.4 THREAT OF SUBSTITUTES 73
5.9.5 THREAT OF NEW ENTRANTS 73
5.10 TARIFF & REGULATORY LANDSCAPE 74
5.10.1 REGULATORY ANALYSIS 74
5.10.1.1 North America 74
5.10.1.1.1 US 74
5.10.1.1.2 Canada 74
5.10.1.2 Europe 74
5.10.1.3 Asia Pacific 74
5.10.1.3.1 China 74
5.10.1.3.2 Japan 75
5.10.1.3.3 India 75
5.10.1.4 Latin America 75
5.10.1.4.1 Brazil 75
5.10.1.4.2 Mexico 75
5.10.1.5 Middle East 76
5.10.1.6 Africa 76
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 11 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.11 PATENT ANALYSIS 78
5.11.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS 78
FIGURE 26 PATENT PUBLICATION TRENDS (JANUARY 2018–MAY 2023) 78
5.11.2 TOP APPLICANTS (COMPANIES) FOR WEARABLE INJECTOR PATENTS 79
FIGURE 27 TOP APPLICANT COMPANIES FOR WEARABLE INJECTOR PATENTS, 2018–2023 79
5.11.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR WEARABLE INJECTOR PATENTS 80
FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR WEARABLE INJECTOR PATENTS, 2018–2023 80
5.12 PRICING ANALYSIS 80
5.12.1 AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYER 80
TABLE 12 AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYERS, 2022 80
5.13 KEY CONFERENCES & EVENTS, 2023–2024 81
TABLE 13 DETAILED LIST OF KEY CONFERENCES & EVENTS IN WEARABLE INJECTORS MARKET, 2023–2024 81
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 82
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES 82
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES (%) 82
5.14.2 BUYING CRITERIA 82
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE DISEASES 82
TABLE 15 KEY BUYING CRITERIA FOR TOP THREE DISEASES 83
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
5.16 UNMET NEEDS 83
5.17 ADJACENT MARKET ANALYSIS 84
FIGURE 31 ADJACENT MARKETS TO WEARABLE INJECTORS MARKET 84
6 WEARABLE INJECTORS MARKET, BY TYPE 85
6.1 INTRODUCTION 86
TABLE 16 WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 86
6.2 ON-BODY WEARABLE INJECTORS 86
6.2.1 ON-BODY WEARABLE INJECTORS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 86
TABLE 17 WEARABLE INJECTORS MARKET FOR ON-BODY WEARABLE INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION) 87
6.3 OFF-BODY WEARABLE INJECTORS 87
6.3.1 EASY AND CONTINUOUS DRUG DELIVERY AT REGULAR INTERVALS TO DRIVE MARKET 87
TABLE 18 WEARABLE INJECTORS MARKET FOR OFF-BODY WEARABLE INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION) 88
6.4 DEVICE-ONLY WEARABLE INJECTORS 89
6.4.1 EASE OF ADMINISTRATION TO SUPPORT MARKET GROWTH 89
TABLE 19 WEARABLE INJECTORS MARKET FOR DEVICE-ONLY WEARABLE INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION) 89
7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY 90
7.1 INTRODUCTION 91
TABLE 20 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 91
7.2 SPRING-BASED TECHNOLOGY 91
7.2.1 MINIMAL DISCOMFORT AND ANXIETY FOR PATIENTS WITH NEEDLE PHOBIA TO PROPEL MARKET 91
TABLE 21 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 92
7.3 MOTOR-DRIVEN TECHNOLOGY 92
7.3.1 TECHNOLOGICAL ADVANCEMENTS AND IMPROVED SAFETY TO AID MARKET GROWTH 92
TABLE 22 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 93
7.4 ROTARY PUMP TECHNOLOGY 93
7.4.1 HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH 93
TABLE 23 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 94
7.5 EXPANDING BATTERY TECHNOLOGY 95
7.5.1 REDUCED PRODUCTION COST AND EASE OF USAGE TO DRIVE MARKET 95
TABLE 24 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 95
7.6 OTHER TECHNOLOGIES 96
TABLE 25 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 96
8 WEARABLE INJECTORS MARKET, BY INDICATION 97
8.1 INTRODUCTION 98
TABLE 26 WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 98
8.2 DIABETES 98
8.2.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET 98
TABLE 27 INSULIN DEVICES AVAILABLE FOR DIABETIC PATIENTS 99
TABLE 28 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2021–2029 (USD MILLION) 100
8.3 IMMUNO-ONCOLOGY 100
8.3.1 INCREASING NUMBER OF CANCER CASES TO BOOST MARKET GROWTH 100
TABLE 29 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 101
8.4 CARDIOVASCULAR DISEASES 101
8.4.1 RISING CASES OF HEART FAILURE AMONG ADULTS TO PROPEL MARKET GROWTH 101
TABLE 30 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2029 (USD MILLION) 102
8.5 CHRONIC PAINS 102
8.5.1 INCREASING RESEARCH IN PAIN MANAGEMENT TO SUPPORT MARKET GROWTH 102
TABLE 31 WEARABLE INJECTORS MARKET FOR CHRONIC PAINS, BY COUNTRY, 2021–2029 (USD MILLION) 103
8.6 OTHER DISEASES 103
TABLE 32 WEARABLE INJECTORS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2029 (USD MILLION) 104
9 WEARABLE INJECTORS MARKET, BY END USER 105
9.1 INTRODUCTION 106
TABLE 33 WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 106
9.2 HOSPITALS AND CLINICS 106
9.2.1 HOSPITALS AND CLINICS TO COMMAND LARGEST END-USER SEGMENT OF END USER DURING STUDY PERIOD 106
TABLE 34 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2029 (USD MILLION) 107
9.3 HOME CARE SETTINGS 107
9.3.1 RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET 107
TABLE 35 WEARABLE INJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION) 108
9.4 OTHER END USERS 109
TABLE 36 WEARABLE INJECTORS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION) 109
10 WEARABLE INJECTORS MARKET, BY REGION 110
10.1 INTRODUCTION 111
FIGURE 32 WEARABLE INJECTORS MARKET: REGIONAL SNAPSHOT 111
TABLE 37 WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD MILLION) 112
10.2 NORTH AMERICA 112
FIGURE 33 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT 113
TABLE 38 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 114
TABLE 39 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 114
TABLE 40 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 115
TABLE 41 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 115
TABLE 42 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 116
10.2.1 NORTH AMERICA: RECESSION IMPACT 116
10.2.2 US 116
10.2.2.1 Favorable reimbursement scenario and high prevalence of chronic diseases to drive market 116
TABLE 43 US: KEY MACROINDICATORS 117
TABLE 44 US: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 117
TABLE 45 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 118
TABLE 46 US: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 118
TABLE 47 US: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 119
10.2.3 CANADA 119
10.2.3.1 Growing biologics market to propel market growth 119
TABLE 48 CANADA: KEY MACROINDICATORS 120
TABLE 49 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 120
TABLE 50 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 121
TABLE 51 CANADA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 121
TABLE 52 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 122
10.3 EUROPE 122
TABLE 53 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 122
TABLE 54 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 123
TABLE 55 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 123
TABLE 56 EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 124
TABLE 57 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 124
10.3.1 EUROPE: RECESSION IMPACT 124
10.3.2 GERMANY 125
10.3.2.1 Favorable government policies for drug development and approval to aid market growth 125
TABLE 58 GERMANY: KEY MACROINDICATORS 125
TABLE 59 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 125
TABLE 60 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 126
TABLE 61 GERMANY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 126
TABLE 62 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 127
10.3.3 FRANCE 127
10.3.3.1 Increased prevalence of diabetes and favorable insurance coverage by SHI to drive market 127
TABLE 63 FRANCE: KEY MACROINDICATORS 127
TABLE 64 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 128
TABLE 65 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 128
TABLE 66 FRANCE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 129
TABLE 67 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 129
10.3.4 UK 129
10.3.4.1 Rising focus on development and promotion of biosimilars and biologics to propel market growth 129
TABLE 68 UK: KEY MACROINDICATORS 130
TABLE 69 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 130
TABLE 70 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 131
TABLE 71 UK: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 131
TABLE 72 UK: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 132
10.3.5 ITALY 132
10.3.5.1 Rising prevalence of diabetes to support market growth 132
TABLE 73 ITALY: MACROECONOMIC INDICATORS 132
TABLE 74 ITALY: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 133
TABLE 75 ITALY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 133
TABLE 76 ITALY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 134
TABLE 77 ITALY: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 134
10.3.6 SPAIN 134
10.3.6.1 Increased preference for less painful drug delivery systems among geriatric population to drive market 134
TABLE 78 SPAIN: MACROECONOMIC INDICATORS 135
TABLE 79 SPAIN: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 135
TABLE 80 SPAIN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 136
TABLE 81 SPAIN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 136
TABLE 82 SPAIN: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 137
10.3.7 REST OF EUROPE 137
TABLE 83 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 137
TABLE 84 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 138
TABLE 85 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 138
TABLE 86 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 139
10.4 ASIA PACIFIC 139
FIGURE 34 ASIA PACIFIC: WEARABLE INJECTORS MARKET SNAPSHOT 140
TABLE 87 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 141
TABLE 88 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 141
TABLE 89 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 142
TABLE 90 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 142
TABLE 91 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 143
10.4.1 ASIA PACIFIC: RECESSION IMPACT 143
10.4.2 JAPAN 143
10.4.2.1 Increasing number of patients suffering from diabetes, CVD, and chronic conditions to drive market 143
TABLE 92 JAPAN: MACROECONOMIC INDICATORS 144
TABLE 93 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 144
TABLE 94 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 145
TABLE 95 JAPAN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 145
TABLE 96 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 146
10.4.3 CHINA 146
10.4.3.1 Favorable government initiatives and improved access to advanced healthcare to drive market 146
TABLE 97 CHINA: MACROECONOMIC INDICATORS 146
TABLE 98 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 147
TABLE 99 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 147
TABLE 100 CHINA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 148
TABLE 101 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 148
10.4.4 INDIA 148
10.4.4.1 Growing burden of diabetes and increasing need to reduce healthcare costs to propel market 148
TABLE 102 INDIA: MACROECONOMIC INDICATORS 149
TABLE 103 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 149
TABLE 104 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 150
TABLE 105 INDIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 150
TABLE 106 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 151
10.4.5 AUSTRALIA 151
10.4.5.1 Favorable government initiatives for diabetes treatment to drive market 151
TABLE 107 AUSTRALIA: MACROECONOMIC INDICATORS 151
TABLE 108 AUSTRALIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 152
TABLE 109 AUSTRALIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 152
TABLE 110 AUSTRALIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 153
TABLE 111 AUSTRALIA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 153
10.4.6 SOUTH KOREA 154
10.4.6.1 Increased number of government initiatives for diabetes management to drive market 154
TABLE 112 SOUTH KOREA: KEY MACROINDICATORS 154
TABLE 113 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 154
TABLE 114 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 155
TABLE 115 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 155
TABLE 116 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 156
10.4.7 REST OF ASIA PACIFIC 156
TABLE 117 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 156
TABLE 118 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 157
TABLE 119 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 157
TABLE 120 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 158
10.5 LATIN AMERICA 158
TABLE 121 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 158
TABLE 122 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 159
TABLE 123 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 159
TABLE 124 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 160
TABLE 125 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 160
10.5.1 LATIN AMERICA: RECESSION IMPACT 161
10.5.2 BRAZIL 161
10.5.2.1 Increasing number of government initiatives for improving healthcare sector to boost market 161
TABLE 126 BRAZIL: MACROECONOMIC INDICATORS 161
TABLE 127 BRAZIL: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 128 BRAZIL: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 162
TABLE 129 BRAZIL: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 163
TABLE 130 BRAZIL: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 163
10.5.3 MEXICO 164
10.5.3.1 Increasing prevalence of diabetes and obesity-related diseases to boost market growth 164
TABLE 131 MEXICO: KEY MACROINDICATORS 164
TABLE 132 MEXICO: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 164
TABLE 133 MEXICO: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 165
TABLE 134 MEXICO: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 165
TABLE 135 MEXICO: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 166
10.5.4 REST OF LATIN AMERICA 166
TABLE 136 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 137 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 167
TABLE 138 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 167
TABLE 139 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 168
10.6 MIDDLE EAST & AFRICA 168
TABLE 140 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD MILLION) 169
TABLE 141 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 169
TABLE 142 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 170
TABLE 143 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 170
TABLE 144 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 171
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 171
10.6.2 GCC COUNTRIES 171
10.6.2.1 Growing incidence of chronic diseases to propel market 171
TABLE 145 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 172
TABLE 146 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 172
TABLE 147 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 173
TABLE 148 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 173
10.6.3 REST OF MIDDLE EAST & AFRICA 173
TABLE 149 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 174
TABLE 150 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 174
TABLE 151 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION) 175
TABLE 152 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION) 175
11 COMPETITIVE LANDSCAPE 176
11.1 INTRODUCTION 176
11.2 KEY STRENGTHS/RIGHT TO WIN 176
FIGURE 35 STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLE INJECTORS MARKET, 2020–2024 177
11.3 REVENUE SHARE ANALYSIS 177
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2018–2022 177
11.4 MARKET SHARE ANALYSIS 178
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 178
11.5 MANUFACTURERS OF WEARABLE DEVICES 179
TABLE 153 LIST OF KEY MANUFACTURERS OF WEARABLE DEVICES 179
11.6 COMPANY EVALUATION MATRIX 179
11.6.1 STARS 179
11.6.2 EMERGING LEADERS 179
11.6.3 PERVASIVE PLAYERS 180
11.6.4 PARTICIPANTS 180
FIGURE 38 COMPANY EVALUATION MATRIX, 2022 180
11.6.5 COMPANY FOOTPRINT 181
TABLE 154 WEARABLE INJECTORS MARKET: OVERALL FOOTPRINT 181
TABLE 155 WEARABLE INJECTORS MARKET: PRODUCT FOOTPRINT 182
TABLE 156 WEARABLE INJECTORS MARKET: REGIONAL FOOTPRINT 183
11.7 START-UP/SME EVALUATION MATRIX 184
11.7.1 PROGRESSIVE COMPANIES 184
11.7.2 RESPONSIVE COMPANIES 184
11.7.3 DYNAMIC COMPANIES 184
11.7.4 STARTING BLOCKS 184
FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022 185
11.7.5 COMPETITIVE BENCHMARKING 185
TABLE 157 DETAILED LIST OF KEY START-UPS/SMES 185
11.8 R&D EXPENDITURE 186
FIGURE 40 R&D EXPENDITURE OF KEY PLAYERS, 2021 VS. 2022 186
11.9 BRAND/PRODUCT COMPARISON 186
TABLE 158 BRAND/PRODUCT COMPARISON OF KEY PLAYERS 186
11.9.1 AMGEN INC. 188
11.9.2 MEDTRONIC 188
11.9.3 INSULET CORPORATION 188
11.9.4 TANDEM DIABETES CARE, INC. 188
11.9.5 UNITED THERAPEUTICS 188
11.9.6 ABBVIE INC. 188
11.9.7 GERRESHEIMER AG 188
11.10 INVESTMENT AND FUNDING SCENARIO 189
FIGURE 41 FUNDING IN WEARABLE INJECTORS MARKET SOARED IN 2022 189
11.10.1 FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION 190
TABLE 159 FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION 190
FIGURE 42 MOST VALUED WEARABLE INJECTORS FIRMS IN 2022 (USD BILLION) 190
11.11 COMPANY FINANCIAL METRICS 190
FIGURE 43 FINANCIAL METRICS OF KEY COMPANIES, 2022 190
11.12 COMPETITIVE SCENARIO 191
11.12.1 PRODUCT LAUNCHES & APPROVALS 191
TABLE 160 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2024 191
11.12.2 DEALS 191
TABLE 161 WEARABLE INJECTORS MARKET: DEALS, 2020–2024 191
11.12.3 OTHER DEVELOPMENTS 192
TABLE 162 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS, 2020–2024 192
12 COMPANY PROFILES 193
12.1 KEY PLAYERS 193
(Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and Competitive threats)*
12.1.1 AMGEN INC. 193
TABLE 163 AMGEN INC.: COMPANY OVERVIEW 193
FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022) 194
TABLE 164 AMGEN INC.: DEALS, 2020–2024 195
TABLE 165 AMGEN INC.: OTHER DEVELOPMENTS, 2020–2024 195
12.1.2 MEDTRONIC 197
TABLE 166 MEDTRONIC: COMPANY OVERVIEW 197
FIGURE 45 MEDTRONIC: COMPANY SNAPSHOT (2022) 198
TABLE 167 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, 2020–2024 199
TABLE 168 MEDTRONIC: DEALS, 2020–2024 199
12.1.3 INSULET CORPORATION 201
TABLE 169 INSULET CORPORATION: COMPANY OVERVIEW 201
FIGURE 46 INSULET CORPORATION: COMPANY SNAPSHOT (2022) 202
TABLE 170 INSULET CORPORATION: PRODUCT LAUNCHES & APPROVALS, 2020–2024 203
TABLE 171 INSULET CORPORATION: DEALS, 2020–2024 203
12.1.4 TANDEM DIABETES CARE, INC. 205
TABLE 172 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 205
FIGURE 47 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022) 205
TABLE 173 TANDEM DIABETES CARE, INC.: DEALS, 2020–2024 206
12.1.5 UNITED THERAPEUTICS CORPORATION 207
TABLE 174 UNITED THERAPEUTICS CORPORATION: COMPANY OVERVIEW 207
FIGURE 48 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2022) 208
TABLE 175 UNITED THERAPEUTICS CORPORATION: DEALS, 2020–2024 209
12.1.6 ABBVIE INC. 210
TABLE 176 ABBVIE INC.: COMPANY OVERVIEW 210
FIGURE 49 ABBVIE INC.: COMPANY SNAPSHOT (2022) 211
TABLE 177 ABBVIE INC.: PRODUCT LAUNCHES & APPROVALS, 2020–2024 211
12.1.7 GERRESHEIMER AG 212
TABLE 178 GERRESHEIMER AG: COMPANY OVERVIEW 212
FIGURE 50 GERRESHEIMER AG: COMPANY SNAPSHOT (2022) 213
TABLE 179 GERRESHEIMER AG: PRODUCT LAUNCHES & APPROVALS, 2020–2024 214
TABLE 180 GERRESHEIMER AG: DEALS, 2020–2024 214
12.1.8 BECTON, DICKISON AND COMPANY 215
TABLE 181 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 215
FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 216
TABLE 182 BECTON, DICKINSON AND COMPANY: DEALS, 2020–2024 217
TABLE 183 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, 2020–2024 217
12.1.9 WEST PHARMACEUTICAL SERVICES, INC. 218
TABLE 184 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 218
FIGURE 52 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022) 219
12.1.10 YPSOMED HOLDING AG 220
TABLE 185 YPSOMED HOLDING AG: COMPANY OVERVIEW 220
FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2022) 221
TABLE 186 YPSOMED HOLDING AG: PRODUCT LAUNCHES & APPROVALS, 2020–2024 222
TABLE 187 YPSOMED HOLDING AG: DEALS, 2020–2024 222
TABLE 188 YPSOMED HOLDING AG: OTHER DEVELOPMENTS, 2020–2024 222
12.1.11 ENABLE INJECTIONS 223
TABLE 189 ENABLE INJECTIONS: COMPANY OVERVIEW 223
TABLE 190 ENABLE INJECTIONS: PRODUCT LAUNCHES & APPROVALS, 2020–2024 223
TABLE 191 ENABLE INJECTIONS: DEALS, 2020–2024 224
TABLE 192 ENABLE INJECTIONS: OTHER DEVELOPMENTS, 2020–2024 224
12.1.12 SUBCUJECT APS 225
TABLE 193 SUBCUJECT APS: COMPANY OVERVIEW 225
12.1.13 CEQUR SIMPLICITY 226
TABLE 194 CEQUR SIMPLICITY: COMPANY OVERVIEW 226
TABLE 195 CEQUR SIMPLICITY: OTHER DEVELOPMENTS, 2020–2024 226
12.1.14 MANNKIND CORPORATION 227
TABLE 196 MANNKIND CORPORATION: COMPANY OVERVIEW 227
FIGURE 54 MANNKIND CORPORATION: COMPANY SNAPSHOT (2022) 227
TABLE 197 MANNKIND CORPORATION: DEALS, 2020–2024 228
TABLE 198 MANNKIND CORPORATION: OTHER DEVELOPMENTS, 2020–2024 228
12.1.15 SONCEBOZ 229
TABLE 199 SONCEBOZ: COMPANY OVERVIEW 229
12.1.16 CC BIO 230
TABLE 200 CC BIO: COMPANY OVERVIEW 230
TABLE 201 CC BIO: DEALS, 2020–2024 230
12.1.17 ELCAM DRUG DELIVERY DEVICES 231
TABLE 202 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW 231
TABLE 203 ELCAM DRUG DELIVERY DEVICES: DEALS, 2020–2024 231
12.1.18 STEVANATO GROUP 232
TABLE 204 STEVANATO GROUP: COMPANY OVERVIEW 232
12.1.19 DEBIOTECH SA 233
TABLE 205 DEBIOTECH SA: COMPANY OVERVIEW 233
12.2 OTHER PLAYERS 234
12.2.1 BEXSON BIOMEDICAL 234
12.2.2 NEMERA 234
12.2.3 LTS LOHMANN THERAPIE-SYSTEME AG 235
12.2.4 KYMANOX CORPORATION 235
12.2.5 NOVO ENGINEERING 236
12.2.6 EOFLOW CO., LTD. 236
*Details on Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 237
13.1 DISCUSSION GUIDE 237
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 244